Acesso livre
Acesso livre

Saúde Pública/Medicina Humanitária

Covid-19: produção global de vacinas é desordenada e a escassez é decorrente de outros fatores além da acumulação por alguns países.

16 Nov, 2021 | 12:43h

Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding – The BMJ

 

Comentário no Twitter

 

Pílula da Pfizer é o mais recente tratamento contra COVID a se mostrar promissor.

16 Nov, 2021 | 12:41h

Pfizer’s pill is the latest COVID treatment to show promise. Here are some more – The Conversation

Conteúdos relacionados:

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Novo relatório da OMS mapeia as barreiras à disponibilidade de insulina e sugere ações que promovam o acesso universal – “100 anos depois de sua descoberta, a insulina ainda está fora do alcance de muitos que vivem com diabetes.”

16 Nov, 2021 | 12:34h

Comunicado de imprensa: New WHO report maps barriers to insulin availability and suggests actions to promote universal access – World Health Organization

Relatório: Keeping the 100-year-old promise: making insulin access universal – World Health Organization

Comentário: Half the People Living with Diabetes Can’t Afford Insulin, WHO Report Shows – Health Policy Watch

Conteúdos relacionados:

Editorial | Insulin for all: a hope yet to be realized.

One hundred years of insulin therapy.

The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.

 

Comentário no Twitter (fio – clique para saber mais)

 

Descarbonização da atenção à saúde em países de baixa e média rendas: potenciais caminhos para emissões zero.

16 Nov, 2021 | 12:18h

Decarbonising healthcare in low and middle income countries: potential pathways to net zero emissions – The BMJ

 

Comentário no Twitter

 

Estudo randomizado fase 4 | Administração de vacinas contra COVID-19 (AstraZeneca ou Pfizer) concomitantemente às vacinas contra influenza sazonal em adultos é segura e preserva a resposta imune de ambas as vacinas.

15 Nov, 2021 | 14:10h

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

Amplo estudo populacional mostra que infecção prévia por SARS-CoV-2 reduz o risco de infecção após vacina de mRNA.

15 Nov, 2021 | 14:08h

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar – JAMA

Comentários:

Vaccine plus previous infection may offer enhanced COVID-19 protection – CIDRAP

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination – News Medical

 

Comentário no Twitter

 

Estudo populacional no Catar mostrou que a efetividade contra doença grave, crítica ou fatal induzida pela variante Delta do SARS-CoV-2 foi de 93,4% para a vacina da Pfizer e de 96,1% para a vacina da Moderna.

15 Nov, 2021 | 14:06h

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar – Nature Medicine

 

Comentário no Twitter

 

[Preprint] Risco de COVID-19 grave é raro entre pessoas com vacinação plena na Inglaterra.

15 Nov, 2021 | 14:01h

Comentário: Risk of severe COVID-19 is rare among fully vaccinated individuals in England – News Medical

Estudo original: Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY – medRxiv

Editorial | COVID está conturbando carreiras científicas pelo mundo.

15 Nov, 2021 | 13:59h

COVID is disrupting scientific careers around the world – Nature

Ver também:

Scientists count the career costs of COVID – Nature

Potentially long-lasting effects of the pandemic on scientists – Nature

O que influencia as respostas das pessoas às mensagens de saúde pública para o controle de riscos e prevenção de doenças infecciosas? Uma breve revisão sistemática das evidências e recomendações.

15 Nov, 2021 | 13:57h

What influences people’s responses to public health messages for managing risks and preventing infectious diseases? A rapid systematic review of the evidence and recommendations – BMJ Open

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.